SCHEDULE: Ronald DePinho Discloses 6.7% Stake in TVARDI THERAPEUTICS

Ronald A. DePinho has filed an amended Schedule 13G, reporting beneficial ownership of 6.7% of TVARDI THERAPEUTICS, INC.'s common stock as of September 30, 2025.

Summary

• Ronald A. DePinho, a U.S. citizen, reported beneficial ownership of 626,190 shares of TVARDI THERAPEUTICS, INC. common stock.
• This ownership represents 6.7% of the company's outstanding common stock.
• The percentage is based on 9,379,332 shares of common stock outstanding as of September 30, 2025, as reported in the Issuer's Form 10-Q filed on November 13, 2025.
• DePinho holds sole voting and sole dispositive power over all 626,190 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing.
• The securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership, which is neutral in sentiment. It provides transparency but does not inherently convey positive or negative news about the company's operations or financial performance.

Future Outlook

NA

Industry Context

This filing indicates a significant individual ownership stake in TVARDI THERAPEUTICS, a company likely operating in the biotechnology or pharmaceutical sector given its name. Such disclosures are routine for investors holding more than 5% of a company's stock and provide transparency regarding major shareholders.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant individual shareholder's stake, which can influence perceptions of insider confidence or stability in the ownership structure.

Key Dates

Keywords

TVARDI THERAPEUTICS, Ronald A. DePinho, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Institutional Ownership, Biotechnology